Publication: Characterization of solid lipid nanoparticles containing caffeic acid and determination of its effects on MCF-7 cells
Date
Authors
Güney, Gamze
Authors
Dikmen, Gökhan
Genç, Lütfi
Advisor
Language
Type
Publisher:
Bentham Science Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Many anticancer drugs that are currently used in cancer treatment are natural products or their analogues by structural modification. Caffeic acid (3, 4-dihydroxycinnamic acid; CA) is classified as hydroxycinnamic acid and has a variety of potential pharmacological effects, including antioxidant, immunomodulatory and anti-inflammatory activities. As a drug carrier, solid lipid nanoparticles (SLNs) introduced to improve stability, provide controlled drug release, avoid organic solvents and are obtained in small sizes. In this study, we developed solid lipid nanoparticles incorporating with caffeic acid using hot homogenization method. Caffeic acid loaded solid lipid nanoparticles were characterized regarding particle size, zeta potential, drug entrapment efficiency, drug release, scanning electron microscopy (SEM) and FT-IR. The effects of caffeic acid loaded solid lipid nanoparticles on MCF-7 cells were determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-dimethyl tetrazolium bromide (MTT) test and Annexin V-PI analysis. As a result, solid lipid nanoparticles could potentially be used for the delivery of caffeic acid and solid lipid nanoparticles formulation enhanced the effects of caffeic acid on MCF-7 cells. Some relevant patents are also referred in this article.
Description
Source:
Keywords:
Keywords
Oncology, Pharmacology & pharmacy, Apoptosis, Caffeic acid (CA), Cancer, Characterization, Drug delivery systems, Solid lipid nanoparticles (SLNs), Phenethyl ester suppresses, Microscale drug particles, Natural-products, Cancer cells, SLN, Immobilization, Proliferation, Cytotoxicity, Metastasis, Inhibition
Citation
Dikmen, G. vd. (2015). "Characterization of solid lipid nanoparticles containing caffeic acid and determination of its effects on MCF-7 cells". Recent Patents on Anti-Cancer Drug Discovery, 10(2), 224-232.